CN108409829A - 通过改进的a蛋白洗脱增强的蛋白质纯化 - Google Patents

通过改进的a蛋白洗脱增强的蛋白质纯化 Download PDF

Info

Publication number
CN108409829A
CN108409829A CN201810100462.9A CN201810100462A CN108409829A CN 108409829 A CN108409829 A CN 108409829A CN 201810100462 A CN201810100462 A CN 201810100462A CN 108409829 A CN108409829 A CN 108409829A
Authority
CN
China
Prior art keywords
polypeptide
protein
antibody
elution
gradient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810100462.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·布朗
C·J·多德
A·N·拉达莫汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108409829(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN108409829A publication Critical patent/CN108409829A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201810100462.9A 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化 Pending CN108409829A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23886709P 2009-09-01 2009-09-01
US61/238,867 2009-09-01
US25343809P 2009-10-20 2009-10-20
US61/253,438 2009-10-20
CN2010800389895A CN102686738A (zh) 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800389895A Division CN102686738A (zh) 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化

Publications (1)

Publication Number Publication Date
CN108409829A true CN108409829A (zh) 2018-08-17

Family

ID=43649614

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810100462.9A Pending CN108409829A (zh) 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化
CN2010800389895A Pending CN102686738A (zh) 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800389895A Pending CN102686738A (zh) 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化

Country Status (14)

Country Link
US (3) US9428548B2 (https=)
EP (2) EP2473617B1 (https=)
JP (1) JP5787891B2 (https=)
KR (1) KR101764449B1 (https=)
CN (2) CN108409829A (https=)
BR (1) BR112012004697B8 (https=)
CA (1) CA2772653C (https=)
ES (1) ES2787234T3 (https=)
HR (1) HRP20200581T1 (https=)
MX (1) MX2012002565A (https=)
PL (1) PL2473617T3 (https=)
RU (1) RU2571929C2 (https=)
SI (1) SI2473617T1 (https=)
WO (1) WO2011028753A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TWI456062B (zh) 2006-09-13 2014-10-11 Abbvie Inc 細胞培養改良
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
MX346115B (es) 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
EP2475678B1 (en) * 2009-09-10 2014-10-08 Lonza Biologics Plc. Method and system for polypeptide purification
RU2648999C2 (ru) * 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
US10189891B2 (en) 2012-03-28 2019-01-29 Ge Healthcare Bioprocess R&D Ab Affinity chromatography matrix
CN104411820B (zh) 2012-06-29 2017-05-03 Emd密理博公司 在蛋白纯化过程中灭活病毒的方法
US8921113B2 (en) 2012-12-21 2014-12-30 Dionex Corporation Buffer kit and method of generating a linear pH gradient
EP2970379B1 (en) * 2013-03-14 2019-05-01 EMD Millipore Corporation Methods of increasing protein purity using protein a based chromatography
NO2994485T3 (https=) * 2013-05-06 2018-06-09
AU2014287044B2 (en) * 2013-07-12 2020-02-06 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
MX380902B (es) * 2013-11-15 2025-03-12 Genentech Inc Métodos para la inactivación viral usando detergentes ecológico.
ES2784749T3 (es) * 2014-03-10 2020-09-30 Richter Gedeon Nyrt Purificación de inmunoglobulina con el uso de etapas de limpieza previa
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN112566930A (zh) * 2018-06-19 2021-03-26 百时美施贵宝公司 使用色谱纯化蛋白质的方法
US11022585B2 (en) 2019-06-09 2021-06-01 Dionex Corporation Methods and systems for optimizing buffer conditions with liquid chromatography
CA3167669A1 (en) * 2020-01-17 2021-07-22 Regeneron Pharmaceuticals, Inc. Hydrophobic interaction chromatography for viral clearance
KR20250011797A (ko) 2023-07-13 2025-01-22 주식회사 녹십자 알부민이 융합된 단백질의 정제방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026891A2 (en) * 2002-09-18 2004-04-01 Genencor International, Inc. Protein purification
CN101120017A (zh) * 2004-08-30 2008-02-06 英国龙沙生物医药股份有限公司 用于纯化抗体的亲和力加离子交换层析
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
CN101213211A (zh) * 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
US20080167450A1 (en) * 2007-01-05 2008-07-10 Hai Pan Methods of purifying proteins

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
DE69023865T2 (de) 1989-07-28 1996-10-17 Wako Pure Chem Ind Ltd Fulgimidderivate.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
CA2113813C (en) 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0733207T3 (da) 1993-12-10 1998-04-20 Genentech Inc Fremgangsmåder til diagnose af allergi og screening af anti-allergi-terapeutika
DK0739214T3 (da) 1994-01-18 1998-10-07 Genentech Inc Fremgangsmåde til behandling af parasitinfektionerunder anvendelse af IgE antagonister
US5702946A (en) 1994-03-03 1997-12-30 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
IL125255A (en) 1996-01-23 2002-02-10 Genentech Inc Anti-cd18 antibodies for treating stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998023761A1 (en) 1996-11-27 1998-06-04 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
EP0981618B2 (en) 1997-05-15 2011-08-24 Genentech, Inc. Anti-apo-2 antibody
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
RU2145610C1 (ru) 1998-12-09 2000-02-20 Общество с ограниченной ответственностью "Протеиновый контур" Способ очистки рекомбинантного эритропоэтина человека
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
AU778199B2 (en) 1999-10-29 2004-11-25 Genentech Inc. Anti-prostate stem cell antigen (PSCA) antibody compositions and methods of use
EP1693108A1 (en) * 2004-12-04 2006-08-23 MERCK PATENT GmbH Mixed-modal anion-exchange type separation material
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
AU2009347206C1 (en) * 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
JP5816170B2 (ja) * 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
WO2015198451A1 (ja) 2014-06-26 2015-12-30 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026891A2 (en) * 2002-09-18 2004-04-01 Genencor International, Inc. Protein purification
CN101120017A (zh) * 2004-08-30 2008-02-06 英国龙沙生物医药股份有限公司 用于纯化抗体的亲和力加离子交换层析
CN101213211A (zh) * 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
US20080167450A1 (en) * 2007-01-05 2008-07-10 Hai Pan Methods of purifying proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAI PAN等: ""Quantitation of soluble aggregates in recombinant monoclonal antibody cell culture by pH-gradient protein A chromatography"", 《ANALYTICAL BIOCHEMISTRY》 *

Also Published As

Publication number Publication date
RU2012112536A (ru) 2013-10-10
CA2772653A1 (en) 2011-03-10
JP5787891B2 (ja) 2015-09-30
BR112012004697A2 (pt) 2015-09-08
EP2473617A1 (en) 2012-07-11
KR101764449B1 (ko) 2017-08-02
KR20120106719A (ko) 2012-09-26
SI2473617T1 (sl) 2020-07-31
RU2571929C2 (ru) 2015-12-27
WO2011028753A1 (en) 2011-03-10
EP2473617B1 (en) 2020-02-26
CA2772653C (en) 2019-06-25
MX2012002565A (es) 2012-05-29
JP2013503877A (ja) 2013-02-04
HRP20200581T1 (hr) 2020-07-10
US9428548B2 (en) 2016-08-30
US20220081466A1 (en) 2022-03-17
US20130041139A1 (en) 2013-02-14
EP3736338A1 (en) 2020-11-11
ES2787234T3 (es) 2020-10-15
PL2473617T3 (pl) 2020-06-29
US20220324905A1 (en) 2022-10-13
BR112012004697B1 (pt) 2021-02-09
BR112012004697B8 (pt) 2021-05-25
CN102686738A (zh) 2012-09-19
EP2473617A4 (en) 2014-04-09

Similar Documents

Publication Publication Date Title
US20220081466A1 (en) Enhanced protein purification through a modified protein a elution
DK1501369T3 (en) Non-affinity purification of proteins
KR101036414B1 (ko) 이온 교환 크로마토그래피에 의한 단백질 정제 방법
US7452539B2 (en) Stabilizing polypeptides which have been exposed to urea
AU2004265253B2 (en) Reducing protein A leaching during protein A affinity chromatography
HK1174666A (zh) 通过改进的a蛋白洗脱增强的蛋白质纯化
HK1233270A1 (en) Reducing protein a leaching during protein a affinity chromatography

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination